Importantly, AMPK activation provided dramatic protection against disease progression in HFD-fed mice, with none of the Pten−/−;AmpkACT mice progressing to adenocarcinoma, whereas 90% of the Pten−/− mice had progressed to adenocarcinoma or advanced adenocarcinoma (Figures 1E and S1E). Here, PRKAA1 is linked to adenocarcinoma.